Pharmedic Pharmaceutical Medicinal JSC (HNX:PMC)
Vietnam · Delayed Price · Currency is VND 139,800
+1,300 (0.94%)
At close: May 18, 2026
HNX:PMC Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 559,506 | 546,567 | 498,185 | 485,186 | 472,274 | 414,232 | |
Revenue Growth (YoY) | 7.06% | 9.71% | 2.68% | 2.73% | 14.01% | -10.10% |
Cost of Revenue | 329,891 | 323,367 | 310,972 | 315,134 | 285,918 | 266,740 |
Gross Profit | 229,615 | 223,200 | 187,213 | 170,053 | 186,356 | 147,492 |
Selling, General & Admin | 129,108 | 125,300 | 96,729 | 85,645 | 95,588 | 74,912 |
Operating Expenses | 129,108 | 125,300 | 96,729 | 85,645 | 95,588 | 74,912 |
Operating Income | 100,507 | 97,900 | 90,484 | 84,408 | 90,768 | 72,580 |
Interest Expense | -738.9 | -302.47 | - | - | - | - |
Interest & Investment Income | 3,852 | 3,852 | 9,557 | 19,853 | 13,178 | 9,363 |
Currency Exchange Gain (Loss) | 1.28 | 1.28 | 2.37 | 17.19 | -43.02 | 27.29 |
Other Non Operating Income (Expenses) | -1,542 | 347.25 | 269.41 | 148.96 | -675.76 | -1,022 |
EBT Excluding Unusual Items | 102,079 | 101,798 | 100,313 | 104,427 | 103,227 | 80,949 |
Gain (Loss) on Sale of Assets | 1,202 | 1,202 | - | 175.45 | 1,253 | 334.97 |
Pretax Income | 103,281 | 102,999 | 100,313 | 104,602 | 104,480 | 81,284 |
Income Tax Expense | 20,751 | 20,695 | 20,180 | 21,038 | 21,064 | 16,524 |
Net Income | 82,530 | 82,305 | 80,133 | 83,564 | 83,416 | 64,760 |
Preferred Dividends & Other Adjustments | 22,222 | 22,222 | 21,636 | 22,562 | 22,522 | 17,485 |
Net Income to Common | 60,308 | 60,083 | 58,497 | 61,002 | 60,894 | 47,275 |
Net Income Growth | -6.36% | 2.71% | -4.11% | 0.18% | 28.81% | -13.21% |
Shares Outstanding (Basic) | 9 | 9 | 9 | 9 | 9 | 9 |
Shares Outstanding (Diluted) | 9 | 9 | 9 | 9 | 9 | 9 |
EPS (Basic) | 6461.77 | 6437.95 | 6268.07 | 6536.47 | 6524.89 | 5065.55 |
EPS (Diluted) | 6461.77 | 6437.95 | 6268.00 | 6536.00 | 6524.89 | 5065.55 |
EPS Growth | -2.03% | 2.71% | -4.10% | 0.17% | 28.81% | -13.21% |
Free Cash Flow | -97,277 | -58,932 | 39,227 | 86,678 | 31,675 | 58,885 |
Free Cash Flow Per Share | -10422.82 | -6314.62 | 4203.23 | 9287.65 | 3394.02 | 6309.63 |
Dividend Per Share | - | - | 2400.000 | 19100.000 | 3000.000 | 2400.000 |
Dividend Growth | - | - | -87.44% | 536.67% | 25.00% | - |
Gross Margin | 41.04% | 40.84% | 37.58% | 35.05% | 39.46% | 35.61% |
Operating Margin | 17.96% | 17.91% | 18.16% | 17.40% | 19.22% | 17.52% |
Profit Margin | 10.78% | 10.99% | 11.74% | 12.57% | 12.89% | 11.41% |
Free Cash Flow Margin | -17.39% | -10.78% | 7.87% | 17.87% | 6.71% | 14.21% |
EBITDA | 114,198 | 109,758 | 101,916 | 96,345 | 103,311 | 86,549 |
EBITDA Margin | 20.41% | 20.08% | 20.46% | 19.86% | 21.88% | 20.89% |
D&A For EBITDA | 13,691 | 11,858 | 11,432 | 11,938 | 12,543 | 13,968 |
EBIT | 100,507 | 97,900 | 90,484 | 84,408 | 90,768 | 72,580 |
EBIT Margin | 17.96% | 17.91% | 18.16% | 17.40% | 19.22% | 17.52% |
Effective Tax Rate | 20.09% | 20.09% | 20.12% | 20.11% | 20.16% | 20.33% |
Revenue as Reported | 559,506 | 546,567 | 498,185 | 485,186 | 472,274 | 414,232 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.